These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 30753483)

  • 1. Immunotherapy for skin cancer.
    Paulson KG; Lahman MC; Chapuis AG; Brownell I
    Int Immunol; 2019 Jul; 31(7):465-475. PubMed ID: 30753483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Possible immunotherapies of skin cancers].
    Lengyel LZS; Gyulai GYR
    Magy Onkol; 2019 Sep; 63(3):239-245. PubMed ID: 31538441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into anti-tumor immunity
    Jani S; Church CD; Nghiem P
    Front Immunol; 2023; 14():1172913. PubMed ID: 37287968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Non-melanoma Skin Cancer.
    Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
    Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
    Vandeven N; Nghiem P
    Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
    Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
    J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
    Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
    Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
    Paulson KG; Bhatia S
    J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
    Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
    J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma.
    Bénigni P; Guénolé M; Bonsang B; Marcorelles P; Schick U; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):17-22. PubMed ID: 31343994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.
    Tabachnick-Cherny S; Pulliam T; Church C; Koelle DM; Nghiem P
    Mol Carcinog; 2020 Jul; 59(7):807-821. PubMed ID: 32219902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
    Swe T; Kim KB
    Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
    Ren Y; Lv Q; Yue W; Liu B; Zou Z
    Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
    Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review.
    Choi FD; Kraus CN; Elsensohn AN; Carley SK; Lehmer LM; Nguyen RT; Linden KG; Shiu J
    J Am Acad Dermatol; 2020 Feb; 82(2):440-459. PubMed ID: 31163235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.